Epidemiology

Original research

Factors associated with syphilis seroprevalence in women with and at-risk for HIV infection in the Women’s Interagency HIV Study (1994–2015)

Kristal J Aaron,1 Ilene Brill,2Zenoria Causey-Pruitt,1 Kerry Murphy,3 Michael Augenbraun,4 Seble Kassaye,5 Joel E Milam,6 Dominika Seidman,7 Audrey L French,8 Stephen J Gange,9 Adaora A Adimora,10 Anandi N Sheth,11 Margaret A Fischl,12 Barbara Van Der Pol,1 Jeanne Marrazzo,1 Mirjam-Colette Kempf,1,2,13 Jodie Dionne-Odom1

ABSTRACT

Objective Syphilis rates among women in the USA more than doubled between 2014 and 2018. We sought to identify correlates of syphilis among women enrolled in the Women’s Interagency HIV Study (WIHS) to inform targeted interventions.

Methods The retrospective cross-sectional analysis of secondary data included women with HIV or at-risk of HIV who enrolled in the multisite US WIHS cohort between 1994 and 2015. Syphilis screening was performed at baseline. Infection was defined serologically by a positive rapid plasma reagin test with confirmatory treponemal antibodies. Sociodemographic and behavioural characteristics stratified by baseline syphilis status were compared for women enrolled during early (1994–2002) and recent (2011–2015) years. Multivariable binomial modelling with backward selection (p>0.2 for removal) was used to model correlates of syphilis.

Results The study included 3692 women in the early cohort and 1182 women in the recent cohort. Syphilis prevalence at enrolment was 7.5% and 3.7% in each cohort, respectively (p<0.01). In adjusted models for the early cohort, factors associated with syphilis included age, black race, low income, hepatitis C seropositivity, drug use, HIV infection and >100 lifetime sex partners (all p<0.05). In the recent cohort, age (adjusted prevalence OR (aPOR) 0.2, 95% CI 0.1 to 0.6 for 30–39 years; aPOR 0.5, 95% CI 0.2 to 1.0 for 40–49 years vs ≥50 years), hepatitis C seropositivity (aPOR 2.1, 95% CI 1.0 to 4.1) and problem alcohol use (aPOR 2.2, 95% CI 1.1 to 4.4) were associated with infection.

Conclusions Syphilis screening is critical for women with HIV and at-risk of HIV. Targeted prevention efforts should focus on women with hepatitis C and problem alcohol use.

INTRODUCTION

Syphilis is an easily detectable and treatable STI; however, rates of syphilis continue to increase among select populations in high-income countries and remains pervasive in low-income and middle-income countries. In 2016, the WHO released a new strategy to combat STIs with goals focused on the elimination of congenital syphilis by implementing comprehensive syphilis screening and treatment among pregnant women and a target of 90% reduction in syphilis incidence globally by 2030. Syphilis screening recommendations for non-pregnant women in the USA are based largely on determination of risk. Acquisition risk is variably defined as a history of syphilis, reporting a sex partner with syphilis, living with HIV or having multiple (>3) sex partners in the past year. Emerging evidence suggests that risk factors for syphilis in the current epidemic may vary for women (drug use) and men (sex with men); and these factors vary by race as well since there is still an enduring high level of racial disparity between syphilis rates among blacks and whites in the USA. Current guidelines recommend more frequent syphilis testing (every 3–6 months) for men who have sex with men with persistent risk behaviours and does not address specific needs for women.

More than 35 000 cases of primary and secondary syphilis were reported to the US Centers for Disease Control and Prevention (CDC) in 2018. Early syphilis rates in women increased 170% from 2014 at 1873 (1.3 cases per 100 000 population) to 5047 (3 cases per 100 000 population) in 2018. The estimated prevalence of early syphilis among US women living with HIV in 2018 was 4%. Syphilis increases the likelihood of HIV acquisition and transmission, and co-infection is common.

STI surveillance reports stratify syphilis rates according to the basic demographic information available (age, sex, race and region). The Women’s Interagency HIV Study (WIHS) is a prospective, multicentre, longitudinal cohort study that has enrolled nearly 5000 women living with HIV and at-risk of HIV infection in the USA since 1994. Additional data collected in research studies such as the WIHS provide information about sensitive behaviours such as drug use and sexual practices using validated questionnaires. These details can offer critical insights about factors associated with syphilis infection.
A nuanced understanding of the risk of syphilis acquisition can be used to define populations of women who are disproportionately impacted by infection. In this analysis, we sought to identify specific risks for syphilis in the early and recent cohorts of WIHS.

METHODS

Study design

This is a retrospective cross-sectional analysis of data collected as part of the prospective WIHS cohort study. It focuses on information collected at enrolment.

Study population

WIHS recruitment and protocol procedures have been published previously. Briefly, enrolment in WIHS occurred during four waves 1994–1995 (2054 HIV+; 569 HIV−), 2001–2002 (737 HIV+, 406 HIV−), 2011–2012 (276 HIV+; 95 HIV−) and 2013–2015 (610 HIV+; 235 HIV−). Women were enrolled by trained staff at 11 sites (Atlanta, Georgia; Birmingham, Alabama; Bronx, New York; Brooklyn, New York; Chapel Hill, North Carolina; Chicago, Illinois; Jackson, Mississippi; Los Angeles, California; Miami, Florida; San Francisco, California; and Washington, DC). HIV-positive or HIV-negative women at risk of HIV acquisition (based on STI history and/or sociobehavioural characteristics) were recruited from facilities, clinics and community venues to include women irrespective of engagement in care. Positive HIV status required a positive ELISA test and a confirmatory western blot. Standardised interviews with structured questionnaires and physical examinations were conducted by study staff at the baseline visit to obtain detailed information from women about demographic, socioeconomic, behaviour and clinical characteristics. Routine syphilis testing was only performed at baseline per study protocol. Women identified as positive for syphilis were either treated by the respective study site or referred for treatment. Clinical staging of syphilis and treatment history was not available for most women in the parent study. For this study, the cohort was divided into two time periods: early enrolment (1994–2002) and recent enrolment (2011–2015). Participants provided written informed consent for screening and enrolment with protocols approved by institutional review boards at each site.

Inclusion and exclusion criteria

Among WIHS participants, the age and racial/ethnic distributions of HIV-negative women are similar to those of HIV-positive women in the cohort (black 72%, white 11%, Hispanic 14% and other 3%), which are generally representative of women living with HIV in the USA. Of both HIV-positive and HIV-negative women in WIHS, most were poor (more than half reported an annual household income of US$<18 000) and over one-third have attained less than a high school education. Self-reported HIV exposure risk at study entry was similar in both HIV-positive and HIV-negative women, including IDU, heterosexual contact and transfusion risk. All cisgender women who enrolled in WIHS between 1994 and 2015 with syphilis screening performed at enrolment were included in this analysis. Syphilis infection was defined as a positive rapid plasma reagin (RPR) test at enrolment with a positive confirmatory treponemal antibody test.

Variables

Independent variables included: age (categorised as 16–29, 30–39, 40–49 and ≥50 years), race (black vs white/other), year of WIHS enrolment (early 1994–1995 and 2001–2002) versus recent (2011–2012 and 2013–2015), low income (defined as an annual income US$<12 000), marital status (defined as married/living with partner vs single/widowed/divorced/separated/other) and hepatitis C (HCV) infection (defined as a HCV antibody positivity). Self-reported information was collected for the following variables: number of lifetime sex partners, transactional sex (defined as ever having sex in exchange for drugs, money or shelter), problem alcohol use (defined as consumption of >7 drinks per week per the National Institute on Alcohol Abuse and Alcoholism, non-injection drug use (IDU) (active or prior use of cocaine/crack, heroin, methamphetamines or other drugs) and IDU (active or prior use of injectable drugs).

Statistical analysis

Baseline characteristics according to syphilis serostatus were compared for early and recent cohort enrollees with HIV infection as an independent variable in the primary analysis, while baseline characteristics according to syphilis serostatus were compared for women living with and without HIV in the secondary analysis. χ² testing was used for comparisons of categorical variables and analysis of variance or the Kruskal-Wallis test was used for continuous variables. Data were missing for <5% for all of the independent variables in this analysis. Some independent variables were correlated: (1) IDU and HCV in primary and secondary analyses, (2) transactional sex and number of lifetime sex partners in the primary analysis and (3) enrolment site and cohort wave in the secondary analysis. We selected HCV and number of lifetime sex partners for the adjusted models in both sets of analyses since these variables had fewer missing data, with the addition of cohort wave in the secondary analyses. In the secondary analysis, correlates of syphilis were analysed according to HIV status.

Univariate logistic regression was performed to identify risk factors for syphilis. HIV status was included in all models due to the cohort characteristics and its relationship with syphilis. Crude prevalence odds ratios (PORs), 95% CIs and p values were calculated. Variables of interest and univariate variables with p<0.2 in early and recent cohorts were also included in the full multivariable log-binomial regression. Backward selection was used to develop a model with all independent variables statistically significantly associated with the outcome at a p value less than or equal to 0.20. One variable, with the highest p value, was removed from the multivariable model at a time until all remaining variables were significantly associated (p<0.2) with syphilis. Adjusted POR (aPOR), 95% CI and p values were calculated.

RESULTS

A total of 4982 women age 16–73 years old were enrolled in the multicentre WIHS cohort between 1994 and 2015. Nearly all (98%) were tested for syphilis. There were 3692 women enrolled between 1994 and 2002 (the early cohort) and 1182 women enrolled between 2011 and 2015 (the recent cohort) (figure 1). Treponemal confirmatory testing varied by site and included fluorescent treponemal antibody absorption test (FTA-ABS) (55%), microhaemagglutination assay for Treponema pallidum antibodies (32%), Treponema pallidum particle agglutination (7%), Treponema pallidum haemagglutination (1%) and enzyme immunoassay (5%). The seroprevalence of syphilis at enrolment was 7.5% in the early cohort and 3.7% in the recent cohort (p<0.001) (figure 1). Of women with syphilis with an RPR titre available, RPR titres were >1:8 in 64/274 women (23%)
Epidemiology

Figure 1  Flow chart for study participants according to baseline syphilis testing and cohort. RPR, rapid plasma reagin; WIHS, Women’s Interagency HIV Study.

in the early cohort and 6/40 women (15%) in the recent cohort (figure 1). The seroprevalence of syphilis at enrolment was 7.4% and 4.4% among women with and without HIV infection, respectively (p<0.001) (online supplemental figure 1).

Baseline characteristics for women enrolled in the early cohorts are shown in table 1. Women with syphilis in the early cohort were more likely to be black (73% vs 56%), HIV-positive (84% vs 73%) and low income (77% vs 59%) compared with women without syphilis (all p<0.05). Unadjusted and adjusted models for syphilis in the early cohort are shown in table 1. In the crude model for the early cohort, syphilis was associated with age category, black race, low income, self-reported history of syphilis, HIV infection, HCV antibody positivity, drug use, problem alcohol use, >10 lifetime sex partners and transactional sex (all p<0.05). Ethnicity and current pregnancy were not associated with syphilis seroprevalence in the crude model for the early cohort. In the adjusted model (n=3562), black race (aPOR 2.0, 95% CI 1.5 to 2.6), drug use (aPOR 3.3, 95% CI 1.9 to 5.4) and >100 lifetime sex partners (aPOR 2.9, 95% CI 2.0 to 4.2) were associated with an increased risk of prevalent syphilis. Factors not associated with syphilis seroprevalence include age category 16–29 years (aPOR 1.2, 95% CI 0.6 to 2.6), 30–39 years (aPOR 1.3, 95% CI 0.7 to 2.6) and 40–49 years (aPOR 0.6, 95% CI 0.3 to 1.3) when compared with women 50 years of age or older and having 11–100 lifetime sexual partners (aPOR 1.2, 95% CI 0.9 to 1.6) compared with ≤10 lifetime sexual partners (table 1).

Baseline characteristics for women enrolled in the recent cohort are shown in table 2. Among women in the recent cohort, women with syphilis were older and more likely to be low income, have HCV antibody, to report problem alcohol use, drug use and transactional sex compared with those without syphilis (all p<0.05) (table 2). In the crude model for the recent cohort, syphilis was associated with age, low income, self-reported history of syphilis, HCV antibody positivity, problem alcohol use, drug use and transactional sex history (all p<0.05) (table 2). Ethnicity and current pregnancy were not associated
with syphilis seroprevalence in the crude model for the recent cohort. In the adjusted model (n=1134), age categories of 30–39 years (aPOR 2.1, 95% CI 1.1 to 4.1) and >100 sexual partners versus 0–10 partners (aPOR 2.6, 95% CI 1.8 to 3.8) were associated with syphilis seroprevalence among women with HIV (online supplemental table 1). Among women without HIV (n=1213), women in the younger age category of 16–29 years (aPOR 0.1, 95% CI 0.04 to 0.5) compared with age ≥50 and those in the recent cohort (aPOR 0.3, 95% CI 0.1 to 0.7) had a reduced risk of syphilis, while black race (aPOR 3.8, 95% CI 1.7 to 8.7) and lower income (aPOR 2.1, 95% CI 1.1 to 4.1) were associated with infection (online supplemental table 2).

**DISCUSSION**

In this analysis of 4874 women enrolled in a multisite US cohort study between 1994 and 2015, the prevalence of syphilis at enrolment was 6.6%. This is ninefold higher than population-level estimates of 0.7% among US women according to the National Health and Nutrition Examination Surveys from 2001 to 2004.19 Our study findings support CDC guidelines for
universal syphilis screening among women living with HIV and at-risk for HIV infection due to their elevated risk.20 21 Risks for syphilis acquisition in women during the 1990s epidemic included black race, drug use, transactional sex and barriers to care.22 23 In this study, we found that age, hepatitis C infection and problem alcohol use were associated with prevalent syphilis in women in the recent cohort.

Younger age in the early cohort and older age in the recent cohorts were relevant, but the significance of specific age categories in this cross-sectional analysis is imprecise since age at acquisition is unspecified. Elevated RPR titres (>1:8) were more common in the early WHS cohort compared with the recent cohort. Specifically, there is evidence of fewer early syphilis infections among the recent cohort as there were five (1.6%) women with titres ≥1:32, while, there were 43 (13.4%) women with titres ≥1:32 in the early cohort. Without additional information about staging, both the age association and RPR titre categories are suggestive of a potential cohort effect. Our interpretation is that some women in the recent cohort (mean age 43 years) may have had persistently reactive low-titre RPR and treponemal antibodies due to prior infection24; however, data regarding prior treatment is not available for individual women in our analysis. Thus, we cannot assume that there was a proportion of serological non-responders or serofast patients, although it is a common outcome of syphilis infection. In a systematic review, the proportion of adults with serological non-response (<4-fold decline in RPR 12 months after syphilis treatment) averaged 11% and the proportion with serofast (persistent low-titre RPR) ranged from 3.5% to 44%.24

Problem alcohol use25 was more commonly reported among women with syphilis, and it was more commonly reported in the recent cohort than in the early cohort (36% vs 18%). This is consistent with other studies suggesting a link between alcohol use, risk behaviours and STI/HIV acquisition risk in women.25 26 In one study, women who consumed alcohol in the past 30 days were more likely to have multiple sexual partners, higher risk sex partners and STI positivity.25 Among 1857 US women with HIV, problem drinking (>7 drinks/week) was associated with having more sex partners.26

---

Table 2: Association between participant characteristics and syphilis status in women in the recent cohort (n=1182)

<table>
<thead>
<tr>
<th>Variable</th>
<th>Syphilis negative, n=1138 (96.3%)</th>
<th>Syphilis positive, n=44 (3.7%)</th>
<th>Syphilis seroprevalence (95% CI)</th>
<th>P value</th>
<th>Syphilis seroprevalence adjusted POR (95% CI)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Demographics</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age category (years)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16–29</td>
<td>84 (7.4)</td>
<td>1 (2.3)</td>
<td>0.14 (0.02 to 1.08)</td>
<td>0.059</td>
<td>0.21 (0.03 to 1.63)</td>
<td>0.136</td>
</tr>
<tr>
<td>30–39</td>
<td>325 (28.6)</td>
<td>3 (6.8)</td>
<td>0.11 (0.03 to 0.37)</td>
<td>&lt;0.001</td>
<td>0.16 (0.05 to 0.56)</td>
<td>0.004</td>
</tr>
<tr>
<td>40–49</td>
<td>414 (36.4)</td>
<td>14 (31.8)</td>
<td>0.41 (0.21 to 0.80)</td>
<td>0.009</td>
<td>0.48 (0.24 to 0.97)</td>
<td>0.042</td>
</tr>
<tr>
<td>≥50</td>
<td>315 (27.7)</td>
<td>26 (59.1)</td>
<td>Ref</td>
<td>Ref</td>
<td>Ref</td>
<td>Ref</td>
</tr>
<tr>
<td>Black race</td>
<td>935 (82.2)</td>
<td>40 (90.9)</td>
<td>2.17 (0.77 to 6.14)</td>
<td>0.144</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hispanic ethnicity</td>
<td>96 (8.4)</td>
<td>1 (2.3)</td>
<td>0.25 (0.03 to 1.85)</td>
<td>0.176</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Single relationship status</td>
<td>778 (69.2)</td>
<td>30 (68.2)</td>
<td>0.96 (0.50 to 1.83)</td>
<td>0.891</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Low income (&lt;$12 000/year)</td>
<td>631 (57.6)</td>
<td>33 (78.6)</td>
<td>2.70 (1.28 to 5.69)</td>
<td>0.009</td>
<td>2.09 (0.97 to 4.49)</td>
<td>0.059</td>
</tr>
<tr>
<td>Self-reported history of syphilis</td>
<td>5 (0.4)</td>
<td>2 (4.6)</td>
<td>10.8 (2.03 to 57.2)</td>
<td>0.005</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Currently pregnant</td>
<td>11 (1.0)</td>
<td>0 (0)</td>
<td>*</td>
<td>*</td>
<td></td>
<td>*</td>
</tr>
<tr>
<td>Medical comorbidities</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HIV infection</td>
<td>825 (72.5)</td>
<td>34 (77.3)</td>
<td>1.29 (0.63 to 2.64)</td>
<td>0.487</td>
<td>1.39 (0.66 to 2.93)</td>
<td>0.390</td>
</tr>
<tr>
<td>Hepatitis C (antibody positive)</td>
<td>146 (12.9)</td>
<td>17 (38.6)</td>
<td>4.27 (2.27 to 8.03)</td>
<td>&lt;0.001</td>
<td>2.05 (1.01 to 4.14)</td>
<td>0.046</td>
</tr>
<tr>
<td>Drug and alcohol use</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Problem alcohol use (&gt;7 drinks/week)</td>
<td>203 (17.8)</td>
<td>16 (36.4)</td>
<td>2.63 (1.40 to 4.95)</td>
<td>0.003</td>
<td>2.21 (1.12 to 4.37)</td>
<td>0.023</td>
</tr>
<tr>
<td>Active or prior drug use</td>
<td>786 (69.1)</td>
<td>38 (86.4)</td>
<td>2.84 (1.19 to 6.77)</td>
<td>0.019</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Active or prior injection drug use</td>
<td>105 (9.2)</td>
<td>6 (13.6)</td>
<td>1.55 (0.64 to 3.76)</td>
<td>0.329</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sexual history</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Number of lifetime sex partners</td>
<td>0.687</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&gt;100</td>
<td>83 (7.3)</td>
<td>2 (4.6)</td>
<td>0.65 (0.15 to 2.84)</td>
<td>0.569</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11–100</td>
<td>483 (42.6)</td>
<td>21 (47.7)</td>
<td>1.18 (0.64 to 2.18)</td>
<td>0.603</td>
<td></td>
<td></td>
</tr>
<tr>
<td>0–10</td>
<td>569 (50.1)</td>
<td>21 (47.7)</td>
<td>Ref</td>
<td>Ref</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Transactional sex (ever)</td>
<td>410 (36.0)</td>
<td>24 (54.6)</td>
<td>2.13 (1.16 to 3.90)</td>
<td>0.014</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Values expressed as n (% of non-missing results); reference levels for variables: age (≥50 years old), race (white, Asian, Native American, Pacific Islander and other), ethnicity (non-Hispanic), relationship status (married/living with a partner), income (US$≥12 000), self-reported history of syphilis (no self-reported history of syphilis), currently pregnant (not pregnant), relationship status (married/living with a partner), income (US$≤12 000); HIV status (HIV negative); hepatitis C (negative), problem alcohol use (≥7 drinks a week); active or historical use of cocaine/crack, heroin, methamphetamine or other non-NUDs drugs (no active or historical drug use); number of lifetime sex partners (0–10 lifetime partners); and history of transactional sex (reporting never having sex for drugs, money or shelter; missing data: income (n=45, 3.8%), self-reported history of syphilis (n=1, 0.1%), marital status (n=13, 1.1%), HCV antibody (n=2, 0.2%), alcohol use (n=1, 0.1%) and number of lifetime sex partners (n=3, 0.3%). In the multivariable model for women in the recent WHS cohorts (2011–2015), there were 1182 women of which data for 1134 were used. Backward selection with an alpha level of removal of 0.2 was used; and the following variables were removed from the model: race, active or historical use of cocaine/crack, heroin, methamphetamines or other non-NUDs drugs and lifetime number of sex partners.

*No outcomes for crude model.

IDU, injection drug use; POR, prevalence OR; WIHS, Women’s Interagency HIV Study.

---
Consistent with other studies, the presence of HCV antibody was associated with syphilis in the early and recent cohort of WIHS. A retrospective analysis of incident syphilis among women enrolled in the US Centers for AIDS Research Network of Integrated Clinical Systems cohort found that independent predictors of incident syphilis included hepatitis C infection, IDU, black race and more recent entry to care.

Low income and a high number of sexual partners were also associated with syphilis in the early cohort, as seen in previous studies. Marked racial inequities were noted among women in the early cohort but not the recent cohort. Differential STI prevalence by region, structural racism and sexual networks may explain some of the disproportionate impact of syphilis on black women. We were unable to comment on geographic region of residence or regional syphilis rates among partners in this study due to collinearity with enrolment timing. The intersectionality between gender-based inequity, racism and low income likely results in an increased vulnerability to STIs among women. These are critical data to collect to inform future studies.

Syphilis screening rates in HIV clinics are often insufficient: only 49% of sexually active women living with HIV were tested at least once for syphilis in the past 12 months. In a study of women living with HIV in California, 51% of Medicare enrollees and 68% of Medicaid enrollees were tested for syphilis in 2010. Our study findings imply that all women living with HIV and at-risk for HIV may need syphilis screening since: (1) infection is often asymptomatic with a painless primary lesion at the site of exposure and (2) rates among women and infants in the USA continue to rise.

The current study has important limitations. Since routine syphilis testing for WIHS participants was only performed at baseline, we were not able to determine incident infection or recent acquisition of syphilis among participants. Also, WIHS participants may not be representative of younger women living with HIV or at-risk for HIV infection. Syphilis seropositivity at enrolment cannot distinguish between active infection, recently treated infection or the serostate fast (ie, persistent reactivity) in the absence of follow-up serologic testing. However, enrolment of US participants over multiple waves during the >20 year span of the study is useful. The diversity of WIHS cohort enrollees from women who engaged and not engaged in medical care mirrors the HIV epidemic. We were unable to analyse geographic differences since the southern sites were only added to the WIHS cohort in 2013.

In conclusion, this study provides useful estimates of syphilis seropositivity and correlates of infection in women living with HIV and at-risk for HIV infection in the USA. Factors associated with syphilis in the current era were similar among women regardless of HIV status. In the midst of a worsening epidemic in the USA, new interventions to increase syphilis screening and treatment in women of all ages are needed. Women with hepatitis C antibody positivity and problem alcohol use may benefit from novel interventions designed to improve syphilis screening and prevention.

Key messages

► Syphilis prevalence was elevated among women living with HIV and at-risk of HIV in a multisite US cohort study.
► Hepatitis C seropositivity was consistently associated with infection in women in both early and recent cohorts.
► Among women with and without HIV, black race and low income were associated with increased risk of syphilis.

Author affiliations

1Department of Medicine/Division of Infectious Diseases, The University of Alabama at Birmingham, Birmingham, Alabama, USA
2Department of Epidemiology, The University of Alabama at Birmingham, Ryals School of Public Health, Birmingham, Alabama, USA
3Department of Medicine/Division of Infectious Diseases, Albert Einstein College of Medicine, Bronx, New York, USA
4Department of Medicine, SUNY Downstate College of Medicine, Brooklyn, New York, USA
5Department of Medicine, SUNY Downstate College of Medicine, Brooklyn, New York, USA
6Department of Epidemiology, Johns Hopkins University, Bloomberg School of Public Health, Baltimore, Maryland, USA
7Department of Medicine and Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA
8Department of Medicine/Division of Infectious Diseases, Emory University, Atlanta, Georgia, USA
9Department of Family, Community & Health Systems, School of Nursing, University of Alabama at Birmingham, Birmingham, Alabama, USA

Handling editor Claudia S Escourt

Acknowledgements We like to thank Ashutosh Tashman, MD, PhD, MSPH, for his careful review and suggestions on the content of this manuscript. Data in this manuscript were collected by the Women’s Interagency HIV Study, now the MACS/WIHS Combined Cohort Study (MWCCS). The contents of this publication are solely the responsibility of the authors and do not represent the official views of the National Institutes of Health.

Contributors The authors’ responsibilities were as follows: KJA: conceived of and designed the study, analysed and interpreted the data, wrote and critically reviewed and edited the manuscript; JD-O: conceived of and designed the study, interpreted the data, wrote and critically reviewed the manuscript; IB: created data set, assisted with data interpretation, critically reviewed the manuscript and assisted with the writing of the manuscript; ZC-P and M-C: interpreted the data, critically reviewed the manuscript and assisted with the writing of the manuscript; BVDF and JM: assisted with study design and critically reviewed the manuscript; KM, MA, SK, JEM, DS, ALF, SIG, AAA, ANS and MAF: critically reviewed the manuscript.

Funding MWCCS (principal investigators): Atlanta CRS (Igwoerha Ofotokun, Anandi Shen and Gina Wingood), U01-HL146241; Baltimore CRS (Todd Brown and Joseph Margolick), U01-HL146201; Bronx CRS (Kathryn Anastas and Anjali Sharma), U01-HL146204; Brooklyn CRS (Deborah Gustafson and Tracey Wilson), U01-HL146202; Data Analysis and Coordination Center (Gyspambe D’Souza, Stephen Gange and Elizabeth Golub), U01-HL146193; Chicago-Cook County CRS (Mardge Cohen and Audrey French), U01-HL146245; Chicago-Northwestern CRS (Steven Wolinsky), U01-HL146240; Connie Wosfy Women’s HIV Study, Northern California CRS (Bradley Aouizerat, Phyllis Yen and Jennifer Price), U01-HL146242; Los Angeles CRS (Roger Deltet), U01-HL146333; Metropolitan Washington CRS (Seble Kassaye and Daniel Menenstein), U01-HL146205; Miami CRS (Maria Alcaide, Margaret Fischl and Deborah Jones), U01-HL146203; Pittsburgh CRS (Jeremy Anderson and Charles Rinaldo), U01-HL146208; UAB-MS CRS (Mirjam-Colette Kempf, Jodie Dionne-Odom and Deborah Konkle-Parker), U01-HL146192; UNC CRS (Adaura Adimora), U01-HL146194. The MWCCS is funded primarily by the National Heart, Lung and Blood Institute (NHLBI), with additional funding from the Eunice Kennedy Shriver National Institute Of Child Health & Human Development, National Institute On Aging, National Institute Of Dental & Craniofacial Research, National Institute Of Allergy And Infectious Diseases, National Institute Of Neurological Disorders And Stroke, National Institute Of Mental Health, National Institute On Drug Abuse, National Institute Of Nursing Research, National Cancer Institute, National Institute on Alcohol Abuse and Alcoholism, National Institute on Deafness and Other Communication Disorders, National Institute of Diabetes and Digestive and Kidney Diseases, National Institute on Minority Health and Health Disparities and in coordination and alignment with the research priorities of the National Institutes of Health, Office of AIDS Research. MWCCS data collection is also supported by UL1-TR000004 (UCSF CTSA), P30-050409 (Atlanta CFAR), P30-050410 (UNC CFAR) and P30-AI-027767 (UAB CFAR). Project support was also provided by 1K23HD090993 (Jodie Dionne-Odom).

Competing interests Dr Van Der Pol receives research support, consulting fees and/or honorarium from the following: Abbott Molecular, BD Diagnostics, BiRx
Epidemiology

Health, BioFire Diagnostics, Hologic, Rheonix, Roche and SpeeDx; Dr. Marrazzo receives research support and/or consulting fees from BD Diagnostics, Gilead, and BioFire Diagnostics. Dr. Adimora has received research funding from Gilead and consulting fees from Merck, Viiv, and Gilead. Dr. Sheth has received research grants from Gilead sciences unrelated to the published work. As a group, we have no other conflicts of interest to report.

Patient consent for publication Not required.

Ethics approval This study received institutional review board approval from the University of Alabama at Birmingham (IRB-300001349).

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement There are no additional unpublished data available. Readers should contact KJA with any inquiries.

ORCID iD
Kristol J Aaron http://orcid.org/0000-0002-9285-7321

REFERENCES